Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Shanghai Haohai Biological Technology Co., Ltd. Class H ( (HK:6826) ) has issued an announcement.
Shanghai Haohai Biological Technology Co., Ltd. has issued a supplemental announcement regarding its connected transaction to acquire equity in Jiangxi Ruiji Bio-Engineering Technology Co., Ltd., elaborating on the valuation basis and ownership structure of the target. The company reiterated that the agreed price of RMB4.53 per share was set after arm’s length negotiations, benchmarked against the target’s last trading price and historical buyback prices, and is positioned at the lower end of industry price-to-sales ratios despite continued revenue growth and stable fundamentals. Management emphasized that recent losses at Jiangxi Ruiji stem from strategic upfront investments in sales, R&D, management expansion and pipeline development in biomedical materials, which are intended to support future commercialization, efficiency and compliance improvements; Haohai expects its acquisition and the grant of nationwide distribution rights to drive higher market share, revenue growth and scale-driven cost reductions. The announcement also clarified that Jiangxi Ruiji is ultimately controlled by investor Zhong Hongbin via a partnership structure, and that the target company and its ultimate owner did not influence the negotiation of the transaction terms, addressing governance and independence concerns for shareholders.
The most recent analyst rating on (HK:6826) stock is a Hold with a HK$27.00 price target. To see the full list of analyst forecasts on Shanghai Haohai Biological Technology Co., Ltd. Class H stock, see the HK:6826 Stock Forecast page.
More about Shanghai Haohai Biological Technology Co., Ltd. Class H
Shanghai Haohai Biological Technology Co., Ltd. is a Chinese biopharmaceutical company focused on biomedical materials and related medical products, with a market presence that relies heavily on product distribution capabilities in Mainland China. The group’s strategy emphasizes expanding its portfolio in advanced biomedical materials and leveraging distribution rights to strengthen its competitive position and capture growth in high-potential therapeutic segments.
Average Trading Volume: 204,388
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$10.71B
Learn more about 6826 stock on TipRanks’ Stock Analysis page.